April 2024 tender notification
Pharmac - Te Pātaka Whaioranga is pleased to provide the latest tender results.
Download the tender notification [PDF 196 KB]
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022, and the 2023/24 Invitation to Tender, dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 May 2024 or the fifth of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the twelfth of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to Pharmac by the fifth (5th) of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Principal Supply brand (Supplier) |
Listing date | Principal Supply date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
| Teriflunomide | Tab 14mg; 28 tablet blister pack | $659.90 | $263.96 | Teriflunomide Sandoz (Sandoz) | 1 November 2024 | 1 April 2025 | Aubagio (Sanofi-Aventi) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Principal Supply brand (Supplier) |
DV limit | Listing date | Principal Supply date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
| Teriflunomide | Tab 14mg; 28 tablet blister pack | $659.90 | $263.96 | Teriflunomide Sandoz (Sandoz) | 5% | 1 November 2024 | 1 April 2025 | Aubagio (Sanofi-Aventi) |
2023/24 Tender – Principal Supply Status applies until 30 June 2027
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Principal Supply brand (Supplier) |
Date of subsidy change | Principal Supply date |
|---|---|---|---|---|---|---|
| Aprepitant1 | Cap 2 x 80 mg and 1 x 125 mg; 3 capsule blister pack | $30.00 | $21.90 | Emend (MSD) | 1 August 2024 | 1 January 2025 |
| Perindopril | Tab 2 mg; 30 tablet blister pack | $1.58 | $1.79 | Coversyl (Servier) | 1 July 2024 | 1 December 2024 |
| Perindopril | Tab 4 mg; 30 tablet blister pack | $2.95 | $2.44 | Coversyl (Servier) | 1 July 2024 | 1 December 2024 |
| Perindopril | Tab 8 mg; 30 tablet blister pack | $5.02 | $3.94 | Coversyl (Servier) | 1 July 2024 | 1 December 2024 |
| Sodium hyaluronate [hyaluronic acid] | Eye drops 1 mg per ml; 10 ml bottle OP | $13.85 | $13.58 | Hylo-Fresh (AFT) | 1 July 2024 | 1 December 2024 |
1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2023/24 Invitation To Tender.
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Principal Supply brand (Supplier) |
Listing date | Principal Supply date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
| Acetylcysteine | Inj 200 mg per ml, 10ml ampoule; 10 ampoule pack | $52.88 | $42.99 | DBL Acetylcysteine (Pfizer) | 1 November 2024 | 1 April 2025 | Martindale Pharma (Max Health) |
| Bimatoprost | Eye drops 0.03%, 3ml dropper bottle OP | $5.95 | $5.15 | Lumigan (AbbVie) | 1 August 2024 | 1 January 2025 | Bimatoprost Multichem (Multichem) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
| Chemical name | Presentation; Pack size and type |
Pack price | Principal Supply brand (Supplier) |
DV Limit | Date of subsidy change | Principal Supply date |
|---|---|---|---|---|---|---|
| Adenosine | Inj 3mg per ml, 10 ml vial; 5 vial pack | $100.00 | Adenosine Baxter (Baxter) | 5% | 1 July 2024 | 1 December 2024 |
| Levosimendan | Inj 2.5 mg per ml, 5 ml vial; 1 vial pack | $509.60 | Simdax (Max Health) | 5% | 1 June 2024 | 1 November 2024 |
6. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Principal Supply brand (Supplier) |
DV Limit | Date of subsidy change | Principal Supply date |
|---|---|---|---|---|---|---|---|
| Aprepitant2 | Cap 2 x 80 mg and 1 x 125 mg; 3 cap pack | $30.00 | $21.90 | Emend (MSD) | 5% | 1 August 2024 | 1 January 2025 |
| Perindopril | Tab 2 mg; 30 tablet blister pack | $1.58 | $1.79 | Coversyl (Servier) | 5% | 1 July 2024 | 1 December 2024 |
| Perindopril | Tab 4 mg; 30 tablet blister pack | $2.95 | $2.44 | Coversyl (Servier) | 5% | 1 July 2024 | 1 December 2024 |
| Perindopril | Tab 8 mg; 30 tablet blister pack | $5.02 | $3.94 | Coversyl (Servier) | 5% | 1 July 2024 | 1 December 2024 |
| Sodium hyaluronate [hyaluronic acid] | Eye drops 1 mg per ml; 10 ml bottle | $13.85 | $13.58 | Hylo-Fresh (AFT) | 5% | 1 July 2024 | 1 December 2024 |
2 This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2023/24 Invitation To Tender.
7. Tenders awarded to pharmaceuticals where at least one other brand is listed.
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Principal Supply brand (Supplier) |
DV Limit | Listing date | Principal Supply date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
| Acetylcysteine | Inj 200 mg per ml, 10ml ampoule; 10 ampoule pack | $52.88 | $42.99 | DBL Acetylcysteine (Pfizer) | 5% | 1 November 2024 | 1 April 2025 | Martindale Pharma (Max Health) |
| Adenosine | Inj 3 mg per ml, 2 ml vial; 5 vial pack | $62.73 | $34.50 | Adsine (Baxter) | 5% | 1 July 2024 | 1 December 2024 | Adenocor (Sanofi) |
| Bimatoprost | Eye drops 0.03%, 3ml dropper bottle | $5.95 | $5.15 | Lumigan (AbbVie) | 5% | 1 August 2024 | 1 January 2025 | Bimatoprost Multichem (Multichem) |
| Cefepime | Inj 1g vial; 1 vial pack | $35.00 | $3.19 | Cefepime-AFT (AFT) | 5% | 1 July 2024 | 1 December 2024 | Cefepime Kabi (Fresenius Kabi) |
| Cefepime | Inj 2g vial; 1 vial pack | $55.00 | $4.99 | Cefepime-AFT (AFT) | 5% | 1 July 2024 | 1 December 2024 | Cefepime Kabi (Fresenius Kabi) |
| Cisplatin3 | Inj 1 mg per ml, 100 ml vial; 1 vial pack | $29.66 | $18.90 | Cisplatin Accord (Accord) | 5% | 1 July 2024 | 1 December 2024 | DBL Cisplatin (Pfizer) |
3The price and subsidy of cispatin (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 December 2024. The subsidy of cisplatin inj 1 mg for ECP (Baxter) will be reduced from $0.31 per 1 mg to $0.19 per 1 mg from 1 July 2024 in Section B of the Pharmaceutical Schedule.
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
| Chemical Name | Line Item |
|---|---|
| Aprepitant (current access) | Cap 40 mg |
| Aprepitant (current access) | Cap 80 mg |
| Aprepitant (current access) | Cap 125 mg |
| Aprepitant (current access) | Cab 165 mg |
| Aprepitant (widened access) | Cap 2 x 80 mg and 1 x 125 mg |
| Aprepitant (widened access) | Cap 40 mg |
| Aprepitant (widened access) | Cap 80 mg |
| Aprepitant (widened access) | Cap 125 mg |
| Aprepitant (widened access) | Cab 165 mg |
| Carbomer | Ophthalmic gel 0.3% |
| Cisplatin | Inj 1 mg per ml, 50 ml |
| Doxorubicin | Inj 10 mg |
| Doxorubicin | Inj 50 mg |
| Doxorubicin | Inj 100 mg |
| Doxorubicin | Inj 200 mg |
| Morphine | Tab immediate-release 10 mg |
| Morphine | Tab immediate-release 20 mg |
| Norethisterone | Tab 350 mcg |
| Octreotide | Inj 50 mcg per ml, 1 ml |
| Octreotide | Inj 100 mcg per ml, 1 ml |
| Octreotide | Inj 500 mcg per ml, 1 ml |
| Pamidronate disodium | Inj 3 mg per ml, 10 ml |
| Pamidronate disodium | Inj 6 mg per ml, 10 ml |
| Pamidronate disodium | Inj 9 mg per ml, 10 ml |
| Pancreatic enzyme | Cap 150 mg |
| Pancreatic enzyme | Cap 300 mg |
| Paracetamol | Inj 10 mg per ml, 100 ml |
| Timolol | Eye drops 0.25%, gel forming |
| Timolol | Eye drops 0.5%, gel forming |
| Tramadol hydrochloride | Oral soln 10 mg per ml |
For products included in the 2021/22, 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.